Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates

Executive Summary

Teva is looking to tap into $6.5bn in US sales of Herceptin and Rituxan in a new deal for North American rights to two of Celltrion's pipeline biosimilars for $160m upfront.

Advertisement

Related Content

Keeping Track: Clarus, Agile and Sunovion Look To Bounce Back From CRLs; FDA To Review Rituximab Biosimilar
Teva To Divest Women's Health, Some Oncology As CEO Search Proceeds
Celltrion's Truxima First Biosimilar MAB In Oncology To Win EU Approval
Teva Hits Pause On Business Development, Even As Some Deals Stumble
Deal Watch: Bristol Leaves Neuropathic Pain Candidate To Lexicon
Inflectra Launch Prep Continues Post-Deadline, Pfizer Says
Teva’s 'Key Ingredient' For Growth: Biosimilars
Teva Embarks On New Phase With FTC Clearance Of Allergan Generics
Inflectra Analytical Data Eased FDA's 'Residual Uncertainty' About Remicade Differences
Celltrion/Pfizer Inflectra Second US Biosimilar; Many Firsts

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097434

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel